Literature DB >> 17649793

Prognostic importance of thymidine kinase in colorectal and breast cancer.

S Svobodova1, O Topolcan, L Holubec, V Treska, A Sutnar, K Rupert, S Kormunda, M Rousarova, J Finek.   

Abstract

BACKGROUND: Thymidine kinase (TK) plays an essential role in the processing of thymidine within the cell and therefore it is an important marker of proliferation, particularly in tumor cells. The aim of our study was to determine the diagnostic, prognostic and predictive importance of TK measurement in cancer. PATIENTS AND METHODS: TK was measured using radioreceptor analysis (RRA) with Immunotech assay kits. The serum level of TK was measured in 1087 patients with malignant disease (355 patients with hematology malignancies and 732 patients with solid tumors).
RESULTS: Serum levels of TK were significantly elevated in inflammatory and immunological diseases in comparison with healthy individuals. Malignant diseases were associated with elevated serum levels of TK only in particular cases (e.g. hematological malignancies, cervical cancer). This marker has a high sensitivity for use as a primary diagnostic tool. It also has a high sensitivity during the follow-up period in breast and colorectal cancer for the prediction of relapse at the time of primary diagnosis and 3 months earlier than the diagnosis of relapse by imaging methods.
CONCLUSION: TK represents a secondary tumor marker which is particularly useful for cancer disease monitoring. Interpretation of this marker must be performed only in association with evaluation of clinical status since all other possible non-specific causes (inflammatory or immunological diseases) of elevated serum levels must be excluded.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17649793

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  12 in total

1.  The Association of Serum Carcinoembryonic Antigen, Carbohydrate Antigen 19-9, Thymidine Kinase, and Tissue Polypeptide Specific Antigen with Outcomes of Patients with Metastatic Colorectal Cancer Treated with Bevacizumab: a Retrospective Study.

Authors:  Ondrej Fiala; Jindrich Finek; Tomas Buchler; Vit Martin Matejka; Lubos Holubec; Jana Kulhankova; Zbynek Bortlicek; Vaclav Liska; Ondrej Topolcan
Journal:  Target Oncol       Date:  2015-12       Impact factor: 4.493

2.  Synthesis and 18F-radiolabeling of thymidine AMBF3 conjugates.

Authors:  Antonio A W L Wong; Jerome Lozada; Mathieu L Lepage; Chengcheng Zhang; Helen Merkens; Jutta Zeisler; Kuo-Shyan Lin; François Bénard; David M Perrin
Journal:  RSC Med Chem       Date:  2020-04-23

3.  Serum thymidine kinase 1 activity in solid tumor (breast and colorectal cancer) patients treated with adjuvant chemotherapy.

Authors:  M Bolayirli; C Papila; G G Korkmaz; B Papila; F Aydoğan; A Karataş; H Uzun
Journal:  J Clin Lab Anal       Date:  2013-05       Impact factor: 2.352

Review 4.  The role of DNA synthesis imaging in cancer in the era of targeted therapeutics.

Authors:  Sridhar Nimmagadda; Anthony F Shields
Journal:  Cancer Metastasis Rev       Date:  2008-12       Impact factor: 9.264

5.  Thymidine kinase 1 as a diagnostic tumor marker is of moderate value in cancer patients: A meta-analysis.

Authors:  Yanqun Xiang; Hua Zeng; Xiang Liu; Hui Zhou; Ling Luo; Chaohui Duan; Xiaohong Luo; Haiyan Yan
Journal:  Biomed Rep       Date:  2013-05-28

6.  Thymidine kinase 1 upregulation is an early event in breast tumor formation.

Authors:  Melissa M Alegre; Richard A Robison; Kim L O'Neill
Journal:  J Oncol       Date:  2012-06-19       Impact factor: 4.375

7.  Biomarker analysis and clinical relevance of TK1 on the cell membrane of Burkitt's lymphoma and acute lymphoblastic leukemia.

Authors:  Evita G Weagel; Wei Meng; Michelle H Townsend; Edwin J Velazquez; Rachel A Brog; Michael W Boyer; K Scott Weber; Richard A Robison; Kim L O'Neill
Journal:  Onco Targets Ther       Date:  2017-09-06       Impact factor: 4.147

8.  The Association of Baseline Serum Tumour Markers with Outcome of Patients with Metastatic Colorectal Cancer Treated with Anti-EGFR Monoclonal Antibodies in the First Line.

Authors:  Ondrej Fiala; Petr Hosek; Ondrej Sorejs; Vaclav Liska; Tomas Buchler; Alexandr Poprach; Radek Kucera; Ondrej Topolcan; Monika Sedivcova; Jindrich Finek
Journal:  J Cancer       Date:  2018-10-20       Impact factor: 4.207

9.  Quaternary structures of recombinant, cellular, and serum forms of thymidine kinase 1 from dogs and humans.

Authors:  Sharif Hanan; Kiran Kumar Jagarlamudi; Wang Liya; He Ellen; Eriksson Staffan
Journal:  BMC Biochem       Date:  2012-06-28       Impact factor: 4.059

10.  A clinical evaluation of the TK 210 ELISA in sera from breast cancer patients demonstrates high sensitivity and specificity in all stages of disease.

Authors:  J Kiran Kumar; A C Aronsson; G Pilko; M Zupan; K Kumer; T Fabjan; J Osredkar; S Eriksson
Journal:  Tumour Biol       Date:  2016-04-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.